Halaman 1 dari 234 hasil
TECHNICAL FIELD
The present invention relates to a novel therapeutic drug for cerebral infarction.
BACKGROUND ART
The pathology of cerebral ischemia is divided into the hyperacute stage (about 3 hours from the onset) and the acute stage (about 2 weeks from the onset). The cerebral ischemic neuronal
TECHNICAL FIELD
The present invention relates to a novel therapeutic drug for cerebral infarction.
BACKGROUND ART
The pathology of cerebral ischemia is divided into the hyperacute stage (about 3 hours from the onset) and the acute stage (about 2 weeks from the onset). The cerebral ischemic neuronal
BACKGROUND OF THE INVENTION
This invention relates to the treatment of myocardial infarction and more particularly to a therapy capable of preventing the reocclusion of a coronary artery which often accompanies the use of thrombolytic agents in the treatment of myocardial infarction. This invention
FIELD OF THE INVENTION
This invention relates to an ultrasonic cerebral infarction therapeutic apparatus, and more specifically, to an ultrasonic cerebral infarction therapeutic apparatus that dissolves thrombus by irradiating an ultrasonic wave onto an embolic site of a cerebral infarction
FIELD OF THE INVENTION
The present invention is concerned generally with cellular compositions and methods for improving cardiac function in a living subject after the occurrence of a myocardial infarction; And is focused in particular upon the preparation and therapeutic use of novel genetically
TECHNICAL FIELD
The present invention relates to a novel preventive and/or therapeutic drug for myocardial infarction.
BACKGROUND ART
In Japan, about 40,000 people are thought to die of acute myocardial infarction each year. In the United States, it is estimated that about 1.5 million people develop
FIELD OF INVENTION
The present invention relates to methods of synthesizing S-allyl-cysteine analogues and their therapeutic composition and applications in treating myocardial infarction.
BACKGROUND OF INVENTION
Myocardial infarction is irreversible necrosis of heart muscle cells caused by ischemic
INCORPORATION BY REFERENCE
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by
INCORPORATION BY REFERENCE
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference
BACKGROUND
INCORPORATION BY REFERENCE
All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by
FIELD OF THE INVENTION
This invention is in the field of immunology/cardiology/biochemistry, and describes more particularly a method to reduce myocardial cell injury during acute myocardial infarction.
BACKGROUND OF THE INVENTION
Mechanical failure of heart muscle is one of the leading causes of
BACKGROUND OF THE INVENTION
Myocardial infarction (MI) and Acute Coronary Syndrome (ACS), e.g., unstable angina, non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial infarction (STEMI), are the leading causes of hospital admissions in industrialized countries. Cardiovascular
FIELD OF THE INVENTION
The described invention relates to infarct area perfusion-improving compositions comprising a chemotactic hematopoietic stem cell product and methods of use thereof in repairing an infarct area injury in the aftermath of an acute myocardial infarction resulting from a natural
BACKGROUND OF THE INVENTION
Eosinophils are pleiotropic multifunctional leukocytes involved in initiation and propagation of diverse inflammatory responses, as well as modulators of innate and adaptive immunity. They represent a small percentage of the total white blood cell population and are
BACKGROUND OF THE INVENTION
The present invention relates to a method for enhancing the targeting capability of an antibody using an antibody-enzyme conjugate and a separate soluble substrate-agent conjugate, wherein the targeted enzyme catalyzes the conversion of a soluble substrate, bearing at